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Solid cancers are a leading cause of death worldwide, primarily due to the failure of eﬀective clinical detection and treatment of
metastatic disease in distant sites. There is growing evidence that the presence of circulating tumor cells (CTCs) in the blood of
cancer patients may be an important indicator of the potential for metastatic disease and poor prognosis. Technological advances
have now facilitated the enumeration and characterization of CTCs using methods such as PCR, ﬂow cytometry, image-based
immunologicapproaches,immunomagnetictechniques,andmicrochiptechnology.However,therarenatureofthesecellsrequires
that very sensitive and robust detection/enumeration methods be developed and validated in order to implement CTC analysis for
widespreaduseintheclinic.Thisreviewwillfocusontheimportanttechnicalandstatisticalconsiderationsthatmustbetakeninto
account when designing and implementing CTC assays, as well as the subsequent interpretation of these results for the purposes
of clinical decision making.
1.Introduction
Solid cancers are a leading cause of morbidity and mortality
worldwide [1, 2], primarily due to the failure of eﬀective
clinical detection and treatment of metastatic disease in
distant sites [3, 4]. The metastatic process is comprised of a
series of sequential steps, and cancer cells must successfully
complete each step in order to give rise to a metastatic
tumor.Thesestepsincludedisseminationofcancercellsfrom
the primary tumor into the bloodstream (intravasation),
survival in the circulation, arrest and extravasation into the
secondary site, and initiation and maintenance of growth
to form clinically detectable metastases [3–7]. Cancer cells
may also disseminate from the primary tumor through the
lymphatic system, although the lack of direct ﬂow from the
lymphatic system to other organs means that tumor cells
escaping via this route must still enter the vascular system
in order to be distributed to distant organs [3, 4, 8].
Given the multistep nature of the metastatic cascade,
there should be several opportunities for early identiﬁcation
and therapeutic targeting of metastatic cells before they
become a clinical problem. Indeed, in cancer patients with
either metastatic or apparently localized disease, there is
growing evidence that the presence of circulating tumor
cells (CTCs) in the blood may be an important indicator
of the potential for metastatic disease and poor prognosis
(reviewed in [9–14]). Although CTCs have been recognized
for over a century [15], a lack of sensitive technology
precluded the detailed study of these cells until recently.
However, technological advances have now facilitated the
identiﬁcation, enumeration, and characterization of CTCs
using methods such as PCR [16–18], ﬂow cytometry2 Journal of Oncology
[19–21], image-based immunologic approaches [22–25],
immunomagnetic techniques [26, 27], and microchip tech-
nology[28].Theabilitytoconsistentlyenumerate,track,and
characterize rare CTCs in cancer patients holds tremendous
promise in terms of identifying the potential for metastatic
diseaseatveryearlystages,managingriskstratiﬁcationinthe
adjuvant setting, monitoring response to treatment, moni-
toring disease recurrence, and the prospective development
of targeted therapies based on molecular characterization of
CTCs [9–14]. However, the rare nature of these cells requires
that very sensitive and robust detection/enumeration meth-
ods be developed and validated in order to implement CTC
analysis for widespread use in the clinic. This review will
therefore focus on the important technical and statistical
considerations that must be taken into account when design-
ing and implementing CTC assays, as well as the subsequent
interpretation of these results for the purposes of clinical
decision making.
2. Technical and Statistical Considerations for
OptimalCTCAnalysis
In metastatic cancer patients, it is estimated that CTCs in the
peripheral blood can occur at a frequency of approximately 1
CTC per 105–107 peripheral blood mononuclear cells, and
this frequency may be even lower (∼1i n1 0 8) in patients
with localized cancer [14, 29–31]. Accurate detection of rare
events such as CTCs requires the ability to detect single
cells with speciﬁc characteristics against a background of
large numbers of other cells. In clinical applications of rare
event detection, there is the added challenge of detecting
the cells of interest in a limited sample volume and being
able to accurately diﬀerentiate these cells from cell debris or
other artifacts of sample preparation within a heterogeneous
population of cells [29]. Furthermore, clinical tests need
to be highly standardized and reproducible in order to be
used for diagnostic, prognostic, and/or predictive purposes
in patients. Assays designed to detect CTCs must therefore
be carefully designed and validated with several important
considerations in mind.
2.1. Speciﬁcity and Sensitivity. The rare nature of CTCs
clearly requires an assay with a high degree of sensitivity in
order to accurately detect cells down to a frequency of 1 in
107-8. However, a second critical requirement centers around
the speciﬁcity of the assay, from the point of view that a
maximum number of true positive events need to be iden-
tiﬁed while at the same time minimizing false positive and
falsenegativeresults.ToidentifyCTCsinblood,investigators
have taken the approach of exploiting phenotypic diﬀerences
between epithelial tumor cells and cells of hematopoietic
origin using markers speciﬁc to each population. For
example, the highly conserved hematopoietic marker CD45
can be successfully employed as an exclusionary marker
to identify leukocytes and eliminate them from subsequent
analysis [32, 33]. However, the identiﬁcation and utilization
of a corresponding CTC-speciﬁc marker has proven to be
moreproblematic,andinfacttheinherentheterogeneityand
genetic instability of tumors [34] make it unlikely that such a
marker even exists. CTCs have instead been identiﬁed using
two alternative approaches; those using tumor type-speciﬁc
markers, and those using epithelial-speciﬁc markers.
Tumor type-speciﬁc markers oﬀer the advantage of only
identifying tumor cells that have disseminated from a par-
ticular tumor type. Markers of this type that have been used
for CTC analysis include mammoglobin, HER2-neu, mucin
1 (breast cancer), prostate speciﬁc antigen (prostate cancer),
carcinoembryonic antigen (colorectal and gastric cancer),
and others [31, 35, 36]. Although these types of markers
may oﬀer the potential advantages of speciﬁcally identifying
tumorcellsratherthanjustepithelialcellsandalsoproviding
some insight into their molecular characteristics, the major
problem with tumor type-speciﬁc markers is that tumors are
inherentlyheterogeneous,andtherearecurrentlynomarkers
known that are expressed by every tumor cell within a given
tumor type. Therefore, an underestimation of actual CTCs
may occur.
In addition to tumor type-speciﬁc markers, a second
approach that has been more widely used for detecting
CTCs involves the use of epithelial-speciﬁc markers. These
types of markers are theoretically expressed by all tumor
cells of epithelial origin as well as by normal epithelial cells,
althoughthelatterareunlikelytobepresentintheperipheral
bloodstream. The most commonly used markers in this
category include epithelial cell adhesion molecule (EpCAM,
also known as ESA, CD326, HEA125, or TACSTD1) and
cytokeratins (CK) 7, 8, 18, 19, and/or 20 [11]. One poten-
tial problem with using epithelial-speciﬁc markers is that,
although the majority of leukocytes do not express epithelial
markers, they have occasionally been observed to become
positive for such antigens when in an activated state [31,
37]. In addition, experimental studies have demonstrated
that more aggressive and/or metastatic tumor cells often
undergo a so-called epithelial-to-mesenchymal transition
(EMT) which facilitates migration and invasion into sec-
ondarymetastaticsites.CellsundergoingEMTshowreduced
cell-cell adhesion, altered morphology, gain of mesenchymal
protein expression, and loss of epithelial marker expression
[38–40]. This may include markers such as EpCAM and CKs
that are used in CTC assays [41]. Therefore, similar to the
issues with tumor type-speciﬁc markers, an underestimation
of actual CTCs numbers (in particular the more metastatic
cells) may occur. However, despite problems with both
marker approaches, EpCAM and CK have emerged as the
most widely accepted CTC markers because of their appli-
cability across numerous diﬀerent tumor types of epithelial
origin [12]. The simultaneous use of multiple markers and
continued research into novel CTC markers will hopefully
lead to enhanced speciﬁcity and sensitivity of CTC assays in
the future.
2.2. Sample Enrichment. I no r d e rt om a x i m i z es e n s i t i v i t y
in rare event detection, most assays aiming to accurately
detect events below a frequency of ∼1:10 4 generally apply
a sample enrichment step to increase the likelihood of
ﬁnding the events of interest. Enrichment approaches
include either positive selection or negative selection usingJournal of Oncology 3
immunomagnetic methods, density gradient centrifugation,
and/or cell size restrictive ﬁltration [11, 32, 33, 42]. Positive
selection involves the use of an antibody against the CTC
target population (i.e., anti-EpCAM) attached to magnetic
beads [26]. In contrast, negative selection uses an antibody
against the nontarget or background population (i.e., anti-
CD45 to identify leukocytes) [32, 33, 42]. Positive selection
approaches usually result in fairly high purity of the sample
recovered, since only CTCs will be selected. However, the
recovery of CTCs may be lower than in negative selection
approaches, since CTCs that have low or absent expression
of EpCAM (or other positive selection markers) may be
lost [41]. In addition, enrichment methods that employ a
minimum number of processing steps are best in order to
minimize CTC loss. Some CTC assays have been performed
directly in whole blood without enrichment [23], although
the stringency of this approach compared to others in the
ﬁeld remains controversial [43].
2.3.StatisticalConsiderations. Clinicalbloodtestsarelimited
by the volume of blood that can be practically and ethically
collected from patients. Since Poisson statistics apply when
counting randomly distributed objects (CTCs) in a certain
volume, an important consideration is whether the blood
sample volume will be adequately large enough to accurately
detect and enumerate a very small number of CTCs [29]. For
cell-based assays such as ﬂow cytometry, a simple calculation
can be used to determine the size of the database/sample that
will provide a given precision:
r =

100
CV
2
,( 1 )
where r is the number of events meeting the required
criterion, and CV is the coeﬃcient of variation of a known
positive control (Table 1). In addition, in order to determine
the statistical variation or range that can be expected around
the “true” value, the standard deviation (SD) must also
be taken into account; where SD equals the
√
target events
counted, and the 95% conﬁdence interval is equal to 2 ×SD.
For example, if the desired CV is 10%, then: r =
(100/10)
2 = 100 events of interest. The true value would
actually be somewhere between 80–120 events in 105 total
events, if the estimated frequency was 1 in 1000. Of note, this
is close to the limit of detection of most routine clinical ﬂow
cytometry tests in the laboratory (i.e., detection of CD34+
cells in hematopoietic stem and progenitor cell transplants).
Even at this level it has taken several years to standardize this
process [44]. From the perspective of CTCs, if 6 CTCs were
detected in a given sample with a CV as high as 40% (in the
rangeofwhathasbeenshowntohaveprognosticsigniﬁcance
in metastatic breast and prostate cancer patients [26, 45]),
then the true value would actually be somewhere between 1
to 11 CTCs in 6.3×106 leukocytes, if the estimated frequency
was 1 in 107. To reduce the CV to ∼10% (and hence improve
the accuracy of the assay), then many more (109)e v e n t s
would need to assessed (Table 1). To put this into perspective
withregardstoapatientbloodsample,10mLofbloodwould
contain ∼5 ×107 leukocytes, assuming a leukocyte count in
the low-normal range (5 × 109/L), which is likely in a cancer
patientonactivetreatment[46].Itisthereforenotsurprising
that analysis of multiple blood samples from the same
patient at the same time point signiﬁcantly improves the
probability of accurately detecting small numbers of CTCs
[29]. These statistical considerations also suggest that some
caution should be employed when using a threshold cutoﬀ
number (i.e., ≥5C T Cv e r s u s<5 CTCs) [26, 45]t os t r a t i f y
cancer patients into poor prognosis versus good prognosis
groups for the purposes of clinical decision making.
Other factors also inﬂuence the statistical accuracy of
a CTC assay, including assay eﬃciency with regards to the
recovery/preservation of CTCs during sample preparation
and/or enrichment (discussed earlier), as well as intra-
operator/interlaboratory variability. The latter is particularly
important when considering implementation of CTC assays
for multicenter studies, especially for those CTC assays
that may have a subjective component to the readout [29].
The success of rare event detection is therefore aﬀected by
many parameters, including quality of the starting sample,
frequency of the events of interest, sample preparation,
speciﬁcity and expression level of the chosen markers,
robustness of the assay, and objective and reproducible
readouts. All of these factors will contribute to the statistical
probability of accurately detecting and quantifying rare
events such as CTCs, and therefore are important to consider
when designing and interpreting CTC assays for clinical use.
3. CurrentlyUsed Methods of CTC Analysis
Several methodological approaches have been used to
detect rare CTCs, including PCR-based approaches [16–
18, 47], ﬂow cytometry [20, 21], image-based immunologic
approaches [23–25], immunomagnetic techniques [26, 27],
andmicrochiptechnology[28].Eachoftheseapproacheshas
distinct advantagesand disadvantages, withthe most notable
being sensitivity and speciﬁcity (Table 2). For example, PCR-
based approaches have the advantage of being very sensitive,
with a demonstrated lower detection limit in the clinical
setting of approximately 1 tumor cell per 1,000,000 host
cells (10−6)[ 16–18]. However, speciﬁcity can be a problem,
since the ampliﬁcation-based nature of PCR can result in
false positives in the presence of even minimal sample
contamination. In contrast, cytometric methods such as ﬂow
cytometryand laserscanning cytometryhavehigh speciﬁcity
due to their capacity for simultaneous analysis of multiple
parametersonacell-by-cellbasis(i.e.,DNAcontent,cellsize,
cell viability, expression of intra- and extracellular markers),
but current systems are limited by their lower sensitivity
(10−4-10−5) and thus by the blood volume that needs to
be analyzed in order to accurately and reproducibly detect
and enumerate very small numbers of CTCs [20, 21, 23, 48–
50]. However, recent advances in cytometry technology will
allow for more parameters to be assessed much more rapidly
than previous generations of instruments. Indeed, current
clinical ﬂow cytometers being marketed can detect up to
10 ﬂuorescence parameters at speeds on many thousand
events/second. A recent paper by He et al. (2007) using a4 Journal of Oncology
Table 1: Determination of database/sample size that will provide a given precision in rare event analysis.(a)
Desired CV (%) → 1 5 10 20 40
r = no. of events of interest → 10000 400 100 25 6
When occurring at a frequency of Total no. of events which must be collected(b)
(%) 1 : n
10 10 105 4 ×103 103 2.5 ×102 6.3 ×101
1 100 106 4 ×104 104 2.5 ×103 6.3 ×102
0.1 1000 107 4 ×105 105 2.5 ×104 6.3 ×103
0.01 10,000 108 4 ×106 106 2.5 ×105 6.3 ×104
0.001 100,000 109 4 ×107 107 2.5 ×106 6.3 ×105
0.00001(c) 10,000,000 1011 4 ×109 109 2.5 ×108 6.3 ×107
(a)Forcell-basedassayssuchasﬂowcytometry,asimplecalculationcanbeusedtodeterminethesizeofthedatabase/samplethatwillprovideagivenprecision:
r = (100/CV)2;w h e r er is the number of events meeting the required criterion, and CV is the coeﬃcient of variation of a known positive control. Modiﬁed
from http://www.icms.qmul.ac.uk/ﬂowcytometry/uses/rareeventanalysis/index.html, Queen Mary, University of London.
(b)With a WBC count in the low-normal range (∼ 5 ×109/L), 10mL of blood would contain ∼ 5 ×107 events.
(c)Estimated frequency of CTCs in the peripheral blood of cancer patients.
folate probe against ovarian cancer cells in twelve patients
showed the ability to detect CTCs in the range of 10–
150CTCs/mL blood in nine patients (8 stage III, 1 stage IV),
with the other three being stage I or II. Visual conﬁrmation
of the cells in the ﬁrst 5 patients was carried out by staining
with CA125. Studies such as this highlight the potential for
exploitation of new surface receptors and new cytometry
technology to identify CTCs [51].
The challenges of CTC analysis have led to the devel-
opment of a number of innovative technologies speciﬁcally
designed for this purpose. The CellSearch Circulating Tumor
Cell Test (Veridex) is the only CTC test that is currently
approvedbytheU.S.FoodandDrugAdministrationforCTC
analysis in metastatic breast, prostate, and colorectal cancers
[26, 52, 53]. The CellSearch system consists of two compo-
nents: the CellTracks AutoPrep System and the CellTracks
Analyzer. The Autoprep System carries out automated and
standardized immunomagnetic cell enrichment using anti-
bodies targeting epithelial cell adhesion molecule (EpCAM),
and subsequent labeling with ﬂuorescent antibodies speciﬁc
for epithelial cells (CK 8, 18, and 19) and leukocytes
(CD45). The CellTracks Analyzer is comprised of a semi-
automated ﬂuorescence microscope and analysis software,
and distinguishes epithelial tumor cells from leukocytes
based on positive staining for CK, negative staining for
CD45, cell size, cell morphology, and positive staining with
the DNA stain 4 , 6-diamino-2-phenylindole (DAPI) [26].
Additional unique and promising systems for CTC
analysis have also recently been reported. For example, the
“CTC-chip” is a silicon microchip containing thousands of
microposts coated with anti-EpCAM. Microﬂuidics is used
to pneumatically push whole blood over the surface of the
CTC-chip, and EpCAM-positive CTCs are captured and
conﬁrmed as CTCs via ﬂuorescence microscopy analysis of
CK expression [28]. Other investigators have shown that
CTCs can be identiﬁed using microﬁltering combined with
electrolysis and RT-PCR [47], or by secretion of epithelial-
speciﬁc or tumor type-speciﬁc soluble proteins using the
EPISPOT technology [54]. Although all of these new
approaches show remarkable sensitivity and the potential
recovery of cells for further molecular characterization,
their development is somewhat less mature than that of
the CellSearch with regards to standardization and clinical
utility.
In summary, several methods are available to detect
CTCs, all of which have distinct advantages and disad-
vantages (Table 2). Numerous clinical studies using these
diﬀerent CTC assays have been conducted across many
diﬀerenttumortypesanddiﬀerentdiseasestages.However,it
remainsdiﬃculttodrawanydeﬁnitiveconclusionsregarding
the value of CTC enumeration for clinical practice, based not
onlyonthevariableassaysusedbutalsoonthefactthatmany
studies have a small number of patients and controls and are
not conducted in multicenter settings [14, 31]. Nevertheless,
results obtained from these studies do suggest a promising
association between CTCs and clinical oncology parameters,
and this is discussed in the next section.
4. Application of CTC Analysisas a Tool for
ClinicalDecisionMaking
4.1. Detection and Enumeration of CTCs in Patients with
Early-Stage Disease. New prognosis tools in the setting of
early-stage cancer have the potential to improve patient
quality of life and enhance clinical decision making. Cur-
rently,theuseofwell-establishedprognostic indicators(such
tumor size or grade) to predict outcome is helpful but
imperfect, owing mainly to tumor plasticity and the reliance
on subjective assessment criteria. Similarly, although some
speciﬁc molecules are currently in clinical use as prognostic
markers of patient outcome (i.e., HER-2 for breast cancer),
these too are imperfect as a result of tumor heterogeneity.
This uncertainty in predicting disease outcome often results
in undertreatment or overtreatment: some patients who
need systemic therapy to treat undetected metastatic disease
maybemissed,andotherpatientswhohavebeensuccessfully
treated by local surgery and radiation and do not requireJournal of Oncology 5
Table 2: Advantages and disadvantages of currently used methods of CTC analysis.
Method Estimated
sensitivity Advantages Disadvantages Selected references
PCR-based
approaches 10−4–10−6
(i) Rapid, quantitative
(ii) High sensitivity
(iii) Small sample volume required
(i) Does not allow for cell-by-cell analysis
(ii) Does not discriminate between viable
and nonviable cells
(iii) Low speciﬁcity
(iv) Technical issues with mRNA
degradation, etc.
[16–18, 47, 55–58]
Flow
cytometry 10−4-10−5
(i) Rapid, quantitative
(ii) Cell-by-cell analysis
(iii) Multiparameter
(iv) High speciﬁcity
(v) Identiﬁcation of viable versus
nonviable cells
(vi) Potential to sort CTCs for
additional characterization
(i) Limited sensitivity
(ii) Requirement for large sample volume
unless sample enrichment used
(iii) No visual conﬁrmation of cell
speciﬁcity
(iv) Technically and analytically
challenging
[20, 21]
Laser
scanning
cytometry
10−4-10−5
(i) Rapid, quantitative
(ii) Cell-by-cell analysis
(iii) Multiparameter
(iv) High speciﬁcity
(v) Identiﬁcation of viable versus
nonviable cells
(vi) Morphological analysis
(i) Limited sensitivity
(ii) Technically and analytically challenging [23–25]
CellSearch
(Veridex) 10−7
(i) High sensitivity and speciﬁcity
(ii) Automated, quantitative
(iii) Highly reproducible
(iv) Moderate sample volume needed
(v) Identiﬁcation of viable versus
nonviable cells
(vi) Commercially available
(vii) Only assay with FDA approval
(i) Limited analysis parameters
(ii) Use of EpCam to capture CTCs may
miss some tumor cells
(iii) Multiple enrichment and processing
steps may result in loss of CTCs
(iv) Partially subjective readout
[26, 45, 52, 53]
CTC
microchip 10−7+
(i) High sensitivity and speciﬁcity
(ii) Quantitative
(iii) Minimal processing and shear stress
(iv) Identiﬁcation of viable versus
nonviable cells
(v) Potential to recover CTCs for
additional characterization
(i) Technology is not commercially
available
(ii) Use of EpCam to capture CTCs may
miss some tumor cells
(iii) Partially subjective readout
[28]
EPISPOT 10−7+
(i) High sensitivity and speciﬁcity
(ii) Quantitative
(iii) Multiparameter
(iv) Only viable tumor cells are detected
(i) Requires 48-hour culture of isolated
CTCs before analysis [54]
systemic therapy may be unnecessarily exposed to toxic side-
eﬀects. There is therefore a clear need for improved tools
that could be used to accurately and reliably predict disease
outcome.
A few studies have demonstrated that CTCs can be
observed in ∼20%–40% of patients with early-stage breast
cancer using PCR-based assays for CK-19 [18, 55–58]a n d
in ∼10% of early-stage patients using the CellSearch system
[35]. In many cases this can be correlated with poorer
outcome with regards to both progression-free and overall
survival, regardless of nodal status or adjuvant therapy [18,
35, 55–58]. Similarly, in patients undergoing curative intent
resection surgery for early-stage colorectal cancer, CTCs
identiﬁed by both CK-20 and CEA mRNA positivity within
24 hours of resection were indicative of relapse, particularly
when combined with nodal status [59]. However, studies in
localized prostate cancer did not show such a relationship,
where analysis of CTCs by either the CellSearch system
or RT-PCR for various transcripts (PSA, KLK2 [kallikrein-
related peptidase 2], and PSCA [prostate stem cell antigen])
demonstrated that CTCs were rarely observed in patients
with localized prostate cancer [60].
At present, not enough evidence is available regarding
how CTC detection and enumeration might be useful for
making clinical decisions in the early-stage/adjuvant setting
[35]. Although the greatest amount of data is available for6 Journal of Oncology
breast cancer, the American Society of Clinical Oncology
(ASCO) Tumor Marker Guidelines Panel has still recom-
mended that currently available CTC results in the early
breast cancer setting must be considered level III at best
e v i d e n c e( w h e r el e v e lIi sb e s te v i d e n c ea n dl e v e lI Vi sw o r s t
evidence), and therefore insuﬃcient to apply to standard
practice at present [61].
4.2. Detection and Enumeration of CTCs in Patients with
Metastatic Disease. Despite signiﬁcant improvements in
detection and treatment of early-stage cancer, the majority
of patients with metastatic cancer will ultimately die of their
disease [1]. In the metastatic setting, the clinical goal is
therefore to choose the therapy regimen that will have the
highest likelihood of response and/or palliation, as well as
the lowest risk of toxicity. This therapy is generallycontinued
until either excessive toxicity occurs or evidence of disease
progression indicates that the therapy is no longer eﬀective
[35]. Therefore, in the metastatic setting, new clinical tools
that can accurately track disease progression and/or predict
response to therapy would be particularly useful.
The majority of evidences supporting the use of CTCs
as clinical decision making tools in patients with metastatic
cancer have been obtained using the CellSearch system
and analysis of 7.5mL blood samples. The ﬁrst of these
major studies was carried out in breast cancer patients,
where Cristofanilli et al. (2004) observed that ∼60%–70%
of metastatic breast cancer patients have ≥2 CTCs, whereas
CTCs were very rarely observed in normal control subjects
[26, 62]. Statistically, it has been shown that patients with
≥5 CTCs at baseline had poorer progression-free and overall
survivalthanpatientswith<5CT Cs[26].Subsequentstudies
demonstrated similar results for metastatic prostate and
colorectal cancers, with the identiﬁed threshold number
needed for stratiﬁcation into the poor prognosis group being
≥5 CTCs at baseline for prostate cancer patients, and ≥3
CTCs at baseline for colorectal patients [45, 52, 53]. These
studies also showed promising results with regards to CTCs
serving as possible surrogate markers for early treatment
response.Inmetastaticbreast,prostate,andcolorectalcancer
patients, a decrease in CTC levels 2–5 weeks after starting
systemic therapy was correlated to improved progression-
free and overall survival [26, 45, 52, 53, 63]. In some
cases, CTC analysis was found to be better for predicting
treatment response than commonly employed methods
such as radiologic assessment (in breast cancer) [64]a n d
measurement of PSA (in prostate cancer) [45].
The observation that CTC levels during treatment may
serve as a marker for treatment eﬃcacy is interesting, but
further studies are needed to validate this as a routine clinical
tool. The Southwest Oncology Group (SWOG S0500) trial
is designed to test the strategy of changing therapy versus
maintaining therapy for metastatic breast cancer patients
who have elevated circulating tumor cell (CTC) levels at ﬁrst
follow-up as assessed by the CellSearch system in 7.5mL
blood samples [65]. Opened in October 2006, this is a
multicenter partially randomized trial that aims to enroll
500 patients with conﬁrmed stage IV (metastatic) disease
undergoing ﬁrst-line chemotherapy. Patients with <5C T C s
at baseline (low risk) will receive standard chemotherapy
without change. Patients with ≥5 CTCs at baseline (high
risk) will undergo a second blood draw after completion of
the ﬁrst course of chemotherapy. Of these patients, women
with <5 CTCs after completing one course of chemotherapy
will continue to receive the same chemotherapy regimen
with no change. Patients with ≥5C T C sa f t e rc o m p l e t i o n
of one course of chemotherapy will be randomized to
either continue with the same chemotherapy or switch
to a diﬀerent regimen. This trial will hopefully provide
information regarding whether it is more eﬀective to change
treatment regimens at the time of CTC increase or wait
until disease progression, thus reﬂecting the eﬃcacy (or
lack of eﬃcacy) of chemotherapy in individual patients and
facilitating better treatment decisions.
Similar to the early-stage setting discussed above, current
ASCO guidelines do not yet support the use of CTC
assays for clinical management decisions in metastatic breast
cancer (or other cancers), mainly due to the wide range of
methodologies being used and the need for further clinical
validation of such tests [57]. However, the uniqueness of
the metastatic setting as often being an end-stage/palliative
situation has led some clinicians to start incorporating
CTCs into their decision making paradigm, in particular for
those patients in which standard clinical, serologic, and/or
radiographic ﬁndings are noninformative [35].
4.3. Statistical Considerations for Application of CTC Enumer-
a t i o nt oC l i n i c a lP r a c t i c e . Although the growing clinical data
supporting the use of CTC detection and enumeration in
clinical oncology is promising, the technical and statistical
limitationsdiscussedearliermustbetakenintoconsideration
before widespread application of such assays into clinical
practice. When the ﬁrst prospective multicenter study of
CTCs using the CellSearch system was published in 2004, the
critical role of 5 CTCs per 7.5mL of blood in determining
poor prognosis versus good prognosis in breast cancer
patients was puzzling, given the inherently rare nature of
these cells and the variability associated with rare event
detection [29]. In fact, this number is more likely to be a
somewhat arbitrary number with more basis in statistical
signiﬁcance between prognosis groups than actual clinical
or biological relevance. From a biological perspective, it is
logical to hypothesize that the greater the number of CTCs
present in a patient’s blood, the more aggressive the disease
and the poorer the outcome will be. However, reanalysis
of the data from Cristofanilli et al. (2004) demonstrated
that median survival does not decrease further when greater
than 5 CTCs (i.e., 6–100 CTCs) versus 5 CTCs are detected
[26, 29]. This was somewhat surprising and suggests that
CTCs need to be present at a certain concentration in
order to be detected at any level. Statistically there may
be a higher probability of correctly identifying CTCs when
>5 are detected, and/or there may be a greater chance of
incorrect identiﬁcation when 1–4 CTCs are detected. This
reanalysis concluded that likely the presence of even 1 CTC
in 7.5mL of blood has clinical relevance with regards to
disease outcome [29]. Combined with the issues of statistical
variability in rare event detection discussed earlier, theseJournal of Oncology 7
results suggest that caution should be employed when using
a threshold number (i.e., ≥5C T Cv e r s u s<5 CTCs) [26,
45] to stratify cancer patients into poor prognosis versus
good prognosis groups for the purposes of clinical decision
making.AmoreappropriateapplicationofCTCanalysismay
be for predictive purposes in terms of determining a patient’s
response to therapy (i.e., by tracking signiﬁcant changes
in CTC numbers within individual patients over time in
response to treatment), and studies such as the SWOG S0500
trial may provide support for this. In addition, a growing
number of studies are moving beyond enumeration and
towards molecular characterization of CTCs. This type of
analysis has less statistical problems associated with it than
those enumeration, and could provide extremely valuable
information regarding the identiﬁcation of speciﬁc targets
for therapy.
4.4. Future Perspectives-Molecular Characterization CTCs.
The possibility of assessing the molecular characteristics of
CTCs holds tremendous potential both from research and
clinical standpoints. Currently, assessment of the primary
tumor for speciﬁc molecular characteristics (i.e., estrogen
receptor [ER] and HER-2 status in breast cancer) is carried
out on primary tumor tissue. However, this assessment is
rarely repeated on metastatic tissues, largely due to the chal-
lenges of ﬁnding and obtaining biopsies of metastatic lesions
[66]. The clinical implications of this are that treatment
decisions regarding targeted therapies such as hormonal
therapy or Herceptin (in the case of HER-2) are made based
on the features of the primary tumor. However, studies have
demonstrated that tumor cells “evolve” during progression
from primary to metastatic disease often displaying very
diﬀerent molecular characteristics in a metastatic site than
in the primary tumor [67–70]. Since CTCs are hypothesized
to be the intermediaries between primary and metastatic
disease and/or surrogates of a patient’s metastatic tumor
[33, 71], molecular characterization of CTCs may provide
an opportunity for noninvasive “real-time” biopsies during
disease progression in order to trackthese molecularchanges
and potentially incorporate them into clinical decision
making.
A number of studies have reported characterization of
speciﬁc molecular features of CTCs, either directly through
RT-PCR or through secondary phenotyping and genotyping
of CTCs after immunomagnetic selection and enumera-
tion (Figure 1). Examples of such molecular characteristics
include EGFR (expression and/or mutation), uPAR, HER2,
IGF1R, and markers for apoptosis such as M30 (useful for
assessing therapy response) [66, 72–76]. Some studies have
also recovered suﬃcient numbers of CTCs to carry out gene
expression proﬁling [77]. Reports have also shown a value
for ﬂuorescence in situ hybridization (FISH) analysis in
CTCs, which allows the assessment of cytogenetic changes
(such as gene translocation or ampliﬁcation) in a patient’s
disease during evolution towards a metastatic phenotype
[66, 76, 78, 79]. For example, Meng et al. (2004) used
FISH to demonstrate that ∼38% of metastatic breast cancer
patients who were initially HER2-negative (based on their
primary tumor) acquired ampliﬁcation of HER-2 in their
CK EGFR
(a)
CK CD44
(b)
CK M30
(c)
Figure 1: Speciﬁc molecular features of CTCs can be analyzed
via secondary phenotyping using the CellSearch system (Veridex)
(a)–(c). Breast cancer CTCs in 7.5mL of blood were processed
on the CellTracks AutoPrep system using the CellSearch CTC
kit and additional characterization antibodies against either (a)
EGFR (Veridex), (b) CD44 (4μg/mL; BD BioSciences), or (c) M30
(3.7μg/mL; Alexis Biochemicals). Samples were then analyzed by
the CellTracks Analyzer II. CTCs were identiﬁed and enumerated
via positive staining for CK and DAPI (respective red and blue
staining in left panels), negative staining for CD45 (not shown),
and size and morphological characteristics. The additional FITC
channel (green staining in right panels) was exploited for identiﬁ-
cation of molecular characteristics in individual CTCs. Expression
of markers such as (a) EGFR and (b) the cancer stem cell marker
CD44 may provide information regarding disease aggressiveness
and/or indicate patient suitability for speciﬁc targeted therapies.
Apoptosis markers such as (c) M30 (caspase-cleaved CK18) and
the corresponding morphological characteristic of apoptotic mem-
brane blebbing could provide information in patients on active
treatment regarding eﬃcacy of therapy and antitumor eﬀects. The
sample shown in (c) was exposed to palitaxel chemotherapy prior
to CTC analysis.8 Journal of Oncology
CTCs. When treated with Herceptin based on CTC HER-
2 ampliﬁcation, some patients demonstrated a partial or
complete response [66].
Although large-scale clinical data is still lacking with
regards to how molecular characterization of CTCs could be
used as a clinical decision making tool, this type of analysis
holds tremendous promise with regards to gaining a better
biologicalunderstandingofthemetastaticprocess,improved
stratiﬁcationofpatients,and/ortheprospectivedevelopment
of tailored, targeted therapies.
5. Summary and Conclusions
In summary, technology development and interest in the
area of CTC analysis is advancing rapidly. CTCs have great
potential as surrogate markers for cancer progression and
treatment, particularly in the metastatic setting. However,
we believe that many technical and statistical issues remain
to be resolved before CTC analysis can be considered for
widespread application to the clinic. The success of CTC
detection and enumeration is inﬂuenced by many param-
eters including quality of the starting sample, frequency of
CTCs, sample preparation, speciﬁcity and expression level
of the chosen markers, robustness of the assay, and objec-
tive and reproducible readouts, including intrareader and
interlaboratory variability. All of these factors will contribute
to the statistical probability of accurately detecting and
quantifying rare events such as CTCs, and therefore are
important to consider when designing and interpreting CTC
assays for clinical use.
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